FDA actions in brief

News
Article

Valsartan (Diovan, Novartis) received an expanded indication for reducing cardiovascular mortality in patients who are at high risk due to left ventricular failure or dysfunction after myocardial infarction.

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.